UCB-话题@MedSci - 梅斯（MedSci）

#UCB#

10篇内容 | 1289人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1482875, encodeId=b69a14828e55c, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准, objectType=article, longId=294569, objectId=656829456957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=656829456957, replyNumber=0, likeNumber=86, createdTime=2022-01-25, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=656829456957, moduleTitle=UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=656829456957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482874, encodeId=e0e514828e4aa, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据, objectType=article, longId=206929, objectId=119120692979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119120692979, replyNumber=0, likeNumber=75, createdTime=2021-02-10, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119120692979, moduleTitle=UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=119120692979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482873, encodeId=e20614828e3ac, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率, objectType=article, longId=195937, objectId=b9d319593e23, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9d319593e23, replyNumber=0, likeNumber=72, createdTime=2020-06-17, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9d319593e23, moduleTitle=AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b9d319593e23)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482872, encodeId=e6d314828e220, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=UCB以2.7亿美元收购Engage公司，及其手持口腔吸入式癫痫急救药物Staccato Alprazolam, objectType=article, longId=195460, objectId=3cd41954601e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cd41954601e, replyNumber=0, likeNumber=67, createdTime=2020-06-09, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cd41954601e, moduleTitle=UCB以2.7亿美元收购Engage公司，及其手持口腔吸入式癫痫急救药物Staccato Alprazolam, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3cd41954601e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482871, encodeId=5acd14828e136, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎, objectType=article, longId=186376, objectId=0af51863e634, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af51863e634, replyNumber=0, likeNumber=70, createdTime=2020-01-18, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af51863e634, moduleTitle=UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0af51863e634)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482870, encodeId=942914828e0bc, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, objectType=article, longId=184396, objectId=e1d618439611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1d618439611, replyNumber=0, likeNumber=49, createdTime=2019-12-09, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1d618439611, moduleTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e1d618439611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482869, encodeId=7e141482869ac, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=美国批准UCB的Cimzia用于牛皮癣的治疗, objectType=article, longId=139439, objectId=66bc13943973, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66bc13943973, replyNumber=0, likeNumber=83, createdTime=2018-05-31, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66bc13943973, moduleTitle=美国批准UCB的Cimzia用于牛皮癣的治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=66bc13943973)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482868, encodeId=34cf148286896, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=UCB的Vimpat在威尔士获得NHS绿灯, objectType=article, longId=131893, objectId=638f13189332, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=638f13189332, replyNumber=0, likeNumber=58, createdTime=2018-03-10, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=638f13189332, moduleTitle=UCB的Vimpat在威尔士获得NHS绿灯, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=638f13189332)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482867, encodeId=6575148286e4b, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=UCB抗癫痫药Vimpat获欧盟批准单药治疗部分发作性癫痫，年销售峰值将达到12亿美元, objectType=article, longId=85434, objectId=cd1a854340b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd1a854340b, replyNumber=0, likeNumber=76, createdTime=2016-12-26, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd1a854340b, moduleTitle=UCB抗癫痫药Vimpat获欧盟批准单药治疗部分发作性癫痫，年销售峰值将达到12亿美元, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cd1a854340b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1482866, encodeId=925d148286651, content=<a href='/topic/show?id=3063180e442' target=_blank style='color:#2F92EE;'>#UCB#</a>, objectTitle=UCB癫痫药物Brivarcetam III期显著改善癫痫发作, objectType=article, longId=38253, objectId=ec213825386, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec213825386, replyNumber=0, likeNumber=85, createdTime=2014-07-27, rootId=0, userName=ms9474365431325850, userId=41d27846369, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec213825386, moduleTitle=UCB癫痫药物Brivarcetam III期显著改善癫痫发作, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ec213825386)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

UCB

2020-05-29

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准

2022-01-25

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据

2021-02-10

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

AAD 2020：UCB的bimekizumab在银屑病方面显示出优于Stelara的皮肤清除率

2020-06-17

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

UCB以2.7亿美元收购Engage公司，及其手持口腔吸入式癫痫急救药物Staccato Alprazolam

2020-06-09

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎

2020-01-18

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira

2019-12-09

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

美国批准UCB的Cimzia用于牛皮癣的治疗

2018-05-31

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

UCB的Vimpat在威尔士获得NHS绿灯

2018-03-10

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

UCB抗癫痫药Vimpat获欧盟批准单药治疗部分发作性癫痫，年销售峰值将达到12亿美元

2016-12-26

ms9474365431325850 (审核中...)

前往app查看评论内容

#UCB#

UCB癫痫药物Brivarcetam III期显著改善癫痫发作

2014-07-27

科室
- - 订阅+
  - 更多科室
工具
服务